Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, announced the publication of a peer reviewed scientific paper describing LDN as a promising treatment in immune related disease and cancer therapies as identified in the lab by Dr. Fengping Shan, IMUN’s Chief Scientific Officer.
The scientific paper by Fengping and Griffin et al. entitled, Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapies was recently published in the online edition of the International Immunopharmacology.
In this paper, the authors describe and analyze naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders.
The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers.
Until now, no review speciﬁc focused on the immunoregulatory functions of LDN has been reported. In this article, we provide a comprehensive summary of the immune-related pharmacological functions and potential mechanisms of LDN.
To our knowledge, LDN could modulate the immune system function of the body to resist an abnormal immune response, and it has been widely accepted by patients with MS, IBD such as CD and many types of malignant tumors. Successful reports of patients with ﬁbromyalgia, ALS and type 1 diabetes treated with LDN are increasing. Future studies and clinical work are warranted to conﬁrm the role of LDN in the treatment of immune-related diseases.
LDN may be considered as a novel immunomodulator and tumor biotherapy agent, which is routinely recommended for people with autoimmune diseases and cancer. At the same time, researchers also found that LDN could control appetite and the intake of high-sugar and high-fat foods and that the eﬀect and mechanism of LDN on body weight control were of great value. Moreover, it is believed that LDN will have more novel dosage forms, such as passive transdermal delivery, liquid nasal spray and sustained-release preparations , in the near future.
Although there are many advantages of LDN therapy, such as low cost, low adverse reaction, high safety, easy availability and better compliance, some issues are still worth noting. Since LDN is thought to play a role in the regulation of inflammatory mediators and the upregulation of endogenous opioid receptors, physicians should be alert to patients who have prior chronic use of LDN in pain management when using exogenous opioids in order to prevent hypersensitivity to exogenous opioids.
Company Name: PublicWire
Contact Person: Dave Donlin
Email: Send Email
Address:5850 TG Lee Blvd, Suite 300
Country: United States